Magrolimab and Pembrolizumab for the Treatment of Relapsed or Refractory Classic Hodgkin Lymphoma

Inclusion Criteria

• Adult >= 18 years old
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
• Biopsy confirmed relapsed or refractory classic Hodgkin lymphoma
• Prior treatment with two or more lines of therapy
• Metabolically active measurable disease by positron emission tomography (PET) imaging, assessable for response according to the 2014 Lugano criteria
• Hemoglobin >= 9.5 g/dL
• Absolute neutrophil count >= 1,000 cells/uL without granulocyte colony stimulating factor (G-CSF) support within 3 weeks prior to enrollment
• Platelet count >= 75,000/uL
• Calculated creatinine clearance > 40 mL/min per the Cockroft-Gault formula
• Total bilirubin < 1.5 x upper limit of normal (ULN) (or < 3.0 x ULN and primarily unconjugated if subject has a documented history of Gilbert’s syndrome)
• Negative urine or serum pregnancy test within 30 days of enrollment and within 72 hours before the first administration of magrolimab for women of childbearing potential
• Women of childbearing potential must be willing to use at least 1 highly effective method of contraception during the study and continue for 4 months after the last dose of magrolimab
• Male subjects who are sexually active with a woman of childbearing potential and who have not had vasectomies must be willing to use a barrier method of contraception during the study and for 4 months after the last dose of magrolimab
• Ability to understand and the willingness to sign the written institutional review board (IRB) approved informed consent document
• Must be willing and able to comply with the clinic visits and procedures outlined in the study protocol

Exclusion Criteria

• Prior treatment with a PD-1 inhibitor within 6 months prior to enrollment
• Prior treatment with antibodies targeting CD47 or SIRPalpha
• Prior allogeneic hematopoietic stem cell transplant
• Systemic autoimmune disease on chronic immunosuppression, defined as >= 10 mg of prednisone daily
• Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of RBCs during the 4 week period prior to screening
• History of hemolytic anemia, immune thrombocytopenic purpura (ITP), or Evan’s syndrome within the last 3 months
• Women who are pregnant or breast feeding
• History of Human Immunodeficiency Virus (HIV) infection, Hepatitis B infection (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C infection (defined as hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
• Second malignancy not in complete remission for at least 1 year, excluding fully resected non melanoma skin cancers or localized prostate cancer
• Active cardiac disease including unstable angina, decompensated congestive heart failure, or severe uncontrolled conduction abnormalities
• History of non-infectious pneumonitis requiring corticosteroids or current pneumonitis
• Significant medical conditions, as assessed by the investigators and investigational new drug (IND) holder, that would substantially increase the risk benefit ratio of participating in the study
• History of psychiatric illness or substance abuse likely to interfere with ability to comply with protocol requirements
• Received a live or live attenuated vaccine within 30 days before the first dose of study intervention
• Received any anti-cancer therapy within 2 weeks prior to the first dose of study intervention